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Available online 16 April 2016Background: Parkinson's disease (PD) is a progressive neurological condition. Levodopa (LD) is the gold standard
therapy for PD patients. Most PD patients in low-income areas cannot afford long-term daily Levodopa therapy.
The aim of our study was to investigate ifMucuna pruriens (MP), a legume with high LD content that grows in
tropical regions worldwide, might be potential alternative for poor PD patients.
Methods:We analyzed 25 samples of MP from Africa, Latin America and Asia. Wemeasured the content in LD in
variousMP preparations (dried, roasted, boiled). LDpharmacokinetics andmotor responsewere recorded in four
PD patients, comparing MP vs. LD + Dopa-Decarboxylase Inhibitor (DDCI) formulations.
Results:Median LD concentration in dried MP seeds was 5.29%; similar results were obtained in roasted powder
samples (5.3%), while boiling reduced LD content up to 70%. Compared to LD + DDCI, MP extract at similar LD
dose provided less clinical beneﬁt, with a 3.5-fold lower median AUC.
Conclusion: Considering the lack of a DDCI, MP therapymay provide clinical beneﬁt only when content of LD is at
least 3.5-fold the standard LD+DDCI. If long-termMP proves to be safe and effective in controlled clinical trials,
it may be a sustainable alternative therapy for PD in low-income countries.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Levodopa1. Introduction
Mucuna pruriens variant utilis (MP) is a leguminous plant belonging
to the Fabaceae family, which grows spontaneously in the tropical and
subtropical areas of the world (Fig. 1). It is considered an invasive
plant, as it grows rapidly without any particular measure needed to en-
sure its growth. AlthoughMP has a high nutritional value due to its con-
tent of nutrients, antinutrients and biologically active compounds [1], it
is not commonly used as food, but rather as a soil fertilizer [2]. The anal-
ysis of MP antinutrients revealed the presence of phytates, tannins,a; MP, Mucuna pruriens; DDCI,
.Pini-CTO, ex ICP, via Bignami 1,
. This is an open access article undersaponins, and compounds with potentially toxic properties, such as al-
kaloids [1,3].
Levodopa is the gold standard in the treatment of Parkinson's dis-
ease (PD). Levodopa was isolated for the ﬁrst time from the legume
Vicia faba in 1910, and its chemical structure was established deﬁnitive-
ly in 1913 [4]. However, MP had been used since ancient times in Ayur-
vedic medicine to treat symptoms of corresponding to PD [5] due to the
high Levodopa concentration in its seeds. Levodopa was isolated from
MP seeds for the ﬁrst time in 1937 [6] and its concentration therein
was estimated to be approximately 4–6% [7]. Preliminary studies carried
out in parkinsonian rats [8], primates [9] and humans [10,11] suggest
that extracts of MP may be used to improve PD motor symptoms,
with a favorable pharmacokinetic proﬁle that may account for a lower
risk and severity of dyskinesias [8,9,11].
Despite being the cheapest treatment for PD, Levodopa therapy is
not currently sustainable for thousands of PD patients with a low-
income, because of limited availability and affordability. [12] Nationalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Distribution ofMucuna growthworldwide (modiﬁed fromhttp://www.discoverlife.
org/mp/20q?search=Mucuna+pruriens&ﬂags=glean:&mobile=close).
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any antiparkinsonianmedication. In Sub-Saharan Africa, approximately
60% of the population liveswith less thanUS$ 2/day and the daily cost of
Levodopa treatment is about 1 US$/day i.e. approx. 50% of a patient's in-
come [12]. On the contrary, themean cost of 1 kg of MP seeds is about 1
US$/kg both in Ghana and Bolivia [Akpalu A., Laguna J. pers. comm.].
One kilogram of MP seeds should be enough for approximately
50 days of treatment, using an average daily dose. Nevertheless, it is
too early for widespread therapeutic use of MP in patients with PD for
a number of reasons. First, little information is available on the exact
content in Levodopa and alkaloids of the various types of MP seeds in
different regions of theworld. To date, there are no practical indicationson howmanyMP seeds are to be used to obtain an established amount
of LD (e.g. number of MP dried seeds needed to obtain clinical response
similar to 100 mg of Levodopa-based medications). In second instance,
differences in cooking methods affect the content of LD in MP [13].
However, no indications are available on the safest cooking method
and its impact on the concentration of LD and antinutrients. Indeed,
MP may be toxic when large unrestricted quantities are ingested due
to LD and, potentially, alkaloids [7,14]. Ghanaian literature suggests
that fresh or driedMP seedsmay be used in humans adopting a number
of safetymeasures, including: eating no N10–15 seeds at a time; remov-
ing teguments; boiling the seeds for at least 40min and throwing away
the cookingwater [15]. Obviously, more scientiﬁc measures are needed
to assess the safety and efﬁcacy ofMP as potential long-term therapy for
PD. Therefore, it is of utmost importance to provide reliable estimates of
the content of LD and antinutrients inMP, because PDpatientsmay self-
medicate inappropriately if theymisinterpret the information aboutMP
that is currently available. Finally, previous animal and clinical studies
comparingMPwith standard LD formulations [8,11] suggested intrinsic
dopa-decarboxylase inhibitor (DDCI)-like activity, but the substances
responsible for this phenomenon have not been identiﬁed. Natural
compounds with intrinsic DDCI activity have been described, one of
which (named genistein) has been found in MP seeds [16]. However,
the ﬁnding of genistein in MP seeds has never been replicated so far.
In the present study, we collected various ecotypes of MP collected
in various areas of the world to measure their content of Levodopa, po-
tentially toxic anti-nutrients (i.e. alkaloids) and the DDCI genistein. In
addition, we investigated Levodopa plasma concentration and clinical
response in four PD patients who self-medicated using MP.
2. Materials and methods
During the 2012–2014 period, we collected 25 samples of
M. pruriens (Table 1). All the samples were examined and identiﬁed as
MP seeds by expert botanists. In MP samples, the concentrations of
Levodopa, alkaloids, a compound with intrinsic DDCI activity (named
genistein) and its precursor (i.e. genistin) were determined using high
performance liquid chromatography together with mass spectrometry
(HPLC-MS) according to standard methods (available upon request).
2.1. Measurement of Levodopa concentration
2.1.1. Dried seeds
The samples of raw seeds were prepared by grinding about 1 g of
seeds ﬁnely in a mortar. The resulting powder was suspended in
50 mL of acid water (containing hydrochloric acid, 0.01 N) and extract-
edwith the help of ultrasound for 24 h. At the end of the extraction pro-
cedure, the aqueous extract was ﬁltered and 1 mL aliquot was collected
and analyzed by HPLC-MS. Besides Levodopa, this technique detected
and quantiﬁed the following compounds: dopamine, adrenaline, nor-
adrenaline, serotonin, retrorsine, crotaline and cytisine.
2.1.2. Cooked seeds (boiling vs. roasting)
Further measurements of Levodopa concentrations were performed
after standardized cooking methods in selected samples of MP seeds.
We focused our analysis on the seeds purchased from authorized mer-
chants in Togo and Bolivia, because these varieties can be easily bought
by patients (compared to the samples provided by the University of
Accra or the USDA; Table 1).
a) BOILING. Standardized boiling (soaked for 15 h+ boiled for 90 min)
with different seed weight/soaking water ratios. The water used for
cooking and soaking was also analyzed.
b) ROASTING. Roasting in a stove at 150° for 15 min, with subsequent
decortication. Whole seeds, decorticated seeds, and teguments
were analyzed separately. The samples of roasted seeds were pre-
pared by weighing about 1 g of the sample and grinding it ﬁnely in
Table 1
Quantiﬁcation of Levodopa inMucuna pruriens samples according to preparation (results in mass%).
N° Code Detailsa Country–continent Sourceb Preparationc Levodopa content (%)
1 Local ecotype White Togo Africa Market Dried seed 5.69
Boiled (3 volumes) 1.69
Boiled (4 volumes) 1.86
Boiled (5 volumes) 0.81
2 Local ecotype Black Togo Africa Market Dried seed 6.41
Boiled (3 volumes) 2.35
Boiled (4 volumes) 1.52
Boiled (5 volumes) 2.55
3 Local ecotype Black Kumasi, Ghana Africa Market Dried seed 6.47
4 GH1739 White Accra, Ghana Africa University Dried seed 1.29
5 GH1740 White Accra, Ghana Africa University Dried seed 3.27
6 GH1741 White Accra, Ghana Africa University Dried seed 5.79
7 GH1742 White Accra, Ghana Africa University Dried seed 4.47
8 GH1743 White Accra, Ghana Africa University Dried seed 6.09
9 GH1744 Mottled Accra, Ghana Africa University Dried seed 4.04
10 GH1745 White Accra, Ghana Africa University Dried seed 3.76
11 GH1746 Mottled Accra, Ghana Africa University Dried seed 8.34
12 GH1747 White Accra, Ghana Africa University Dried seed 5.29
13 GH3957 Mottled Accra, Ghana Africa University Dried seed 4.75
14 GH3972 White Accra, Ghana Africa University Dried seed 1.21
15 GH3973 Black Accra, Ghana Africa University Dried seed 6.26
16 PI227479 Mottled Costa Rica Latin America USDA Dried seed 5.84
17 PI337098 Local name Velvet bean Brazil Latin America USDA Dried seed 4.56
18 PI364362 Local name Velvet bean Mozambique Africa USDA Dried seed 4.89
19 PI365411 Local name Velvet bean Mozambique Africa USDA Dried seed 4.46
20 PI365415 Local name Velvet bean Mozambique Africa USDA Dried seed 4.53
21 PI365414 Local name Velvet bean Mozambique Africa USDA Dried seed 3.52
22 PI494877 Color ash. Local name Coffee. Zambia Africa USDA Dried seed 7.49
23 Local ecotype Black Santa Cruz, Bolivia Latin America Market Dried seed 6.57
Roasted powder 5.7
24 Local ecotype White Santa Cruz, Bolivia Latin America Market Dried seed 9.49
Roasted powder 5.04
25 Local ecotype India Asia Drug store in Germany Roasted powder 5.3
Abbreviations: USDA, ARS. Plant Genetic Resources Conservation Unit. Grifﬁn, Georgia, USA.
a Include color and/or USDA Plantid code details.
b The Germplasm from the USDA is being distributed by the U.S. National Plant Germoplasm System (NPGS) for education, agricultural research or breeding purposes.
c Inhibitionwas carried out using three volumes of deionizedwater for eachweight unit of the dried seeds. Several volumes of deionizedwaterwere added to the imbibed seeds vs. the
initial dried seed weight for cooking.
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the same method as described above.2.2. Measurement of alkaloids and genistein concentration
2.2.1. Alkaloids
The analyses were carried out by gas chromatography-mass spec-
trometry (GC-MS) and by gas chromatography-Thermal Energy Analy-
sis (GC-TEA), a selective detector of molecules containing nitrogen
atoms. The following alkaloids were investigated: 7-cyano-1,2,3,4-
tetrahydroisoquinoline, N-methylcytisine, sparteine and lupanine. The
identiﬁcation and quantiﬁcation of these analytes were carried out by
using standard methods available on the market and by constructing
calibration curves according to the method of the external reference
standard. The analyses carried out by GC-TEA in search of nitrogenous
compounds were carried out on the same extracts in dichloromethane
analyzed by GC-MS. The compounds that generated a detectable signal
were quantiﬁed as lupanine, constructing a calibration curve. The anal-
yses performed by GC-MS and GC-TEA were performed using equip-
ment settings that enabled a direct comparison between retention
times in order to achieve correspondence between the signals recorded
byGC-MSandpeaks recorded byGC-TEA. Speciﬁcally, capillary columns
having the same type of stationary phase were used and the same ther-
mal ramp was set up.
Genistein and its precursor genistin were measured in dried seeds
and roasted powder of Bolivian MP samples, roasted powder from
Indian samples (samples 23 and 25 in Table 1), and marketed MP-derived extracts (Table 2). The samples of roasted seeds were prepared
according to the procedure described above and analyzed by HPLC-MS.2.3. Levodopa plasma concentrations and pharmacodynamics
During 2013–2014, four patients with idiopathic PD were examined
at our Institute, who reported to self-medicate with MP, either alone
(n = 2) or together with standard anti-PD therapy (n = 2). Three
male patients were regularly purchasing and taking MP extract in cap-
sules three-to-four times daily (each capsule contained 300 mg of MP-
derived powder) manufactured in Italian licensed drugstores from
rawmaterial obtained in India. A fourth female patient withmotor ﬂuc-
tuations and dyskinesiaswas takingMP powder from seeds she had ob-
tained by herself in Bolivia (Table 2). We measured plasma Levodopa
concentrations at ﬁxed time-points over a 3-h period after intake of
Levodopa + DDCI (either carbidopa or benserazide) or MP powder in
the morning on two consecutive days, after overnight withdrawal of
usual anti-PD therapy (at least 12 h). Acute Levodopa challenge dose
was calculated according to the patient's usual fasting ﬁrst morning
dose. Measured pharmacokinetic variables included time to peak
(tmax), peak plasma Levodopa concentration (Cmax) and the area
under the plasma concentration–time curve (AUC) [17]. The Uniﬁed
Parkinson's Disease Rating scale motor score (UPDRS-III) and the Ab-
normal Involuntary Movements Scale (AIMS) were used to assess
motor response and dyskinesias, respectively. The study protocol was
carried out in compliance with the Declaration of Helsinki and its fur-
ther amendments. Written informed consent was obtained from all pa-
tients and all subjects included in video.
Table 2
Levodopa plasma pharmacokinetic measures and pharmacodynamic response.
Features Patient 1 Patient 2 Patient 3 Patient 4a
Gender M M M F
Age (years) 85 69 62 52
Disease duration (years) 8 6 4 10
Body weight 48.5 73 72 68
UPDRS part III – Off 29 22 10 28
Hoehn and Yahr stage – Off 2 2 1 3
Levodopa daily dose (mg/day) 300 400 300 475
Concomitant DA agonists (type, mg/day) – ROP, 6 mg – ROP, 16 mg
Duration of chronic MP therapy (years) 2 2 2 0.5
Levodopa + DDCI challenge
Levodopa dose (mg) 150 150 150 100
Weight adjusted Levodopa dose (mg/kg) 3.2 2.1 2.1 1.5
Motor response UPDRS III at 90 min 21 12 8 11
Change vs. OFF (%) 27.6 45.4 20.0 60.7
UPDRS III at 180 minb – – – 22
AIMS at 90 min 0 0 0 10
Cmax (μg/mL) 2.43 3.5 5.7 0.92
tmax (min) 45 30 15 45
AUC (μg/mL) × min 212.0 241.1 239.6 55.3
Mucuna pruriens challenge
Levodopa content in MP (%)c 15 15 15 5.7
Levodopa content in MP (mg) 135 180 180 400
Weight-adjusted Levodopa content (mg/kg) 2.8 2.5 2.5 5.9
Levodopa ratio MP:LD + DDCI 0.9: 1 1.2: 1 1.2: 1 4: 1
Motor response UPDRS III at 90 min 24 18 8 10
Change vs. OFF (%) 17 18 20 63.6
Change vs. LD + DDCI at 90 mind −10% −27% 0% +3%
UPDRS III at 180 minb – – – 11
AIMS at 90 min 0 0 0 5
LD pharmacokinetics Cmax (μg/mL) 1.82 1.2 2.05 1.53
tmax (min) 45 30 15 30
AUC (μg/mL) × min 98.4 65.2 86.8 95.5
AUC ratio LD + DDCI:MPe 1.96 4.64 3.47 0.58
Abbreviations: AUC, Area under the plasma concentration-time curve; Cmax, peak plasma levodopa concentration; DDCI, Dopa decarboxylase inhibitor (i.e. benserazide or carbidopa); LD,
Levodopa; tmax, time to peak plasma levodopa concentration; UPDRS III, Uniﬁed Parkinson's Disease Rating Scale, motor examination.
a Considering the median ratio between the AUC on LD + DDCI vs. MP (namely LD without DDCI) was 3.5, the MP dose in this patient was calculated using a 1:4 ratio.
b UPDRS III was performed at 180 min only in patient#4.
c MPpowderdaily amountpatients used to take at homebefore the baseline visit. Levodopa content in each samplewas calculated. Patients#1 to#3were assumingMPextractmanufactured
in Italian licensed drugstores from rawmaterial obtained in India. Patient#4 was assuming MP powder obtained from roasted seeds (Table 1, sample 23).
d Calculated as [(UPDRS III at 90 min on MP – UPDRS III at 90 min on LD + DDCI) / UPDRS III in OFF] ∗ 100.
e Adjusted for Levodopa dose 150 mg.
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3.1. Measurement of Levodopa concentration
All results of laboratory analyses are summarized in Table 1.
3.1.1. Dried seeds
HPLC-MS analyses detected only Levodopa. The other compounds
sought by this techniquewere not found in any of the samples analyzed
(b10 mg/kg in seed samples and b2 mg/L in water samples). Median
[25-75IQR] concentration of Levodopa in the powder of roasted seeds
was 5.29% [4.5–6.3]. Levodopa concentration was veriﬁed also
correcting for protein content.
3.1.2. Boiled seeds
Results of imbibition tests are reported in Table 1. No Levodopa was
found in cooking or imbibition water. Median [25-75IQR] Levodopa
concentration after boilingwas reduced by 70.3% [68.6–70.4] compared
to dried seeds.
3.1.3. Roasted seeds
Median [25-75IQR] concentration of Levodopa in the powder of
roasted seeds was 5.3% [5.2–5.5], similar to raw dried seeds. We here-
with describe the preparation method followed by a Bolivian neurolo-
gist (J.L.) with a long-standing clinical experience in the use of MP
seeds in the treatment of PD: (a) roasting in a pan for 15 min;(b) waiting for all the teguments to burst (the noise resembles popcorn
bursting); (c) removing from theﬁre and hulling; (d) roasted seedsmay
be crunched or ground in a little coffee grinder, passed through a sieve
and added to soup or water as a powder (Supplementary video).
3.1.4. Marketed extract of MP
The concentration of Levodopa in the MP-derived extract that pa-
tients purchase and take home as capsules was 15% (corresponding to
45 mg of Levodopa for each 300 mg capsule).
3.2. Measurement of alkaloids, genistein and genistin concentrations
3.2.1. Alkaloids
The searchwas carried out on all the seeds available (rawand dried),
as well as on the boiled seeds, cooking water, imbibition water and
roasted seeds. No alkaloids were found either by GC-MS or by HPLC-
MS. GC-MS detected a series of peaks that could have been generated
by compounds with isoquinoline, pyrrolidine and steroid nuclei. These
peaks were semi-quantiﬁed using a lupanine external standard. GC-
TEA analyses generated chromatograms that showed peaks due to the
presence of nitrogenous compounds that could not be identiﬁed, but
that are reasonably generated by alkaloids. However, in view of the
high complexity of the matrixes analyzed and of the multiplicity of ni-
trogenous compounds that they could contain, it was not possible to es-
tablish with certainty whether a substance detected actually was an
alkaloid or not in the absence of the speciﬁc reference standard.
Fig. 2. Levodopa plasma pharmacokinetic measures.
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We did not ﬁnd either genistein or genistin in all the MP samples
tested, including marketed samples.
3.3. Levodopa plasma pharmacokinetic and pharmacodynamic measures
In the three PD patients assuming marketed extracts of MP, the me-
dian [25-75IQR] ratio between the AUC obtained from 150 mg
Levodopa + Benserazide and the AUC obtained with the MP extract
was 3.47[2.7–4.0] (Table 2). Motor response at 90 min and 180 min
from intake of MP extract was variable, ranging from 27% worsening
to approx. the same extent of improvement in UPDRS-III scores versus
an equal amount of dispersible Levodopa + Benserazide (Table 2). No
dyskinesias were recorded in these patients (they have never described
any dyskinesias so far).
A fourth female patientwith advanced PD and a history ofmotor ﬂuc-
tuations and dyskinesias reported that she was taking MP powder (from
seeds she had obtained in Bolivia) on top of her standard anti-PD therapy.
Considering themedian 3.5-fold lowerAUCmeasure obtained comparing
marketed MP powder with Levodopa + Benserazide, we administered
MPpowder calculating a 4-fold Levodopa content. In this case, the explor-
ative 4:1 ratio also considered the approximate 5-fold lower bioavailabil-
ity of Levodopa in the central nervous system without a DDCI [11,18].
Compared to Levodopa + DDCI, MP induced a similar reduction in
UPDRS-III scores at 90 min, but considerably better motor performance
at 180 min, due to a 30-min longer duration of ON condition (180 min
vs. 210 min, respectively) with reduced dyskinesias (Table 2).
4. Discussion
All the types of MP seeds (utilis variant) we analyzed from different
countries worldwide contain Levodopa, with a median percentage of
5.3%. We did not identify a more promising ecotype, hence the most
easily available ecotype in the various geographical areas may be used.
Nonetheless, the wide range of concentrations (from 1.2% to 9.5%)
does not allow an a priori estimate of Levodopa content in individual
MP samples. These ﬁndings highlight an important take-homemessage
of the present study: the therapeutic dose required to treat PD patients
must be based on an a priorimeasurement of Levodopa concentration in
the speciﬁc MP ecotype to avoid unpleasant side effects.
Overall, no known alkaloids were detected in all the MP samples
tested. This ﬁnding supports the safety of long-term consumption of
MP, when daily dose is controlled [7–9,19]. However, it is certainly ad-
visable to eat MP after cooking to reduce the ingestion of the
antinutrients that usually occur in raw legumes (phytic acid, tannins, sa-
ponins, etc.) and after removing its teguments, to avoid side effects due
to fermentation.
Another issue addressed in the present study was the potential dif-
ference in Levodopa concentration between dried MP seeds and differ-
ent cooking methods. Compared to dried seeds, boiling greatly reduced
the concentration of Levodopa in the seeds, while roasting seem to play
a minor effect on the concentration of Levodopa. On the other hand,
roasting seems to be a better cookingmethod than boiling for a number
of other reasons: (a) it is easier to standardize, as it avoids the need to
measure the amount of cooking/soaking water, the measurement of
temperature and cooking time; (b) it facilitates tegument removal (teg-
uments contain antinutrients); (c) it just requires a pan and a little
grinder (that can be replaced by a mortar); (d) roasted powder is safe
from a hygienic point of view; (e) it is easy to store even for a long time.
Levodopa is unaffordable in most low-income regions of the world
[12], it is therefore mandatory to identify an interventional strategy de-
signed to ease the economic burden of pharmacologicalmanagement of
PD in developing countries. Levodopa-based strategy using MP seeds
maywell ﬁt this objective. However, this means investigating the safety
and efﬁcacy of dosage regimens in order to minimize side effects and
tailor them to the needs of the patient. In tropical areas, the cost ofhome preparation of MP roasted powder is negligible and it is easy to
store for a long time. Levodopa-based therapy usingMPmay be consid-
ered a potential alternative therapy for PD in developing countries, be-
cause it is very easy to ﬁnd at local markets and easy to grow in all
tropical areas, with a low-cost preparation method. On the other
hand, marketed capsules of MP extract in many developed countries
and/or on the web do not meet these requirements, because they
have elevated production costs and overall low mean LD content.
A ﬁnal issue concerningMP relates to clinical effects in patients with
PD. Preclinical and clinical studies suggest substantial effects of MP in
the improvement of parkinsonian features with reduced dyskinesias
compared to standard Levodopa + DDCI formulations [8,9,11,20,21].
These effects were thought to be associatedwith amore favorable phar-
macokinetic proﬁle and with potential intrinsic DDCI-like activity [8,9].
In the ﬁnal part of this study, we investigated Levodopa plasma concen-
trations and motor response in a small number of patients (who were
already taking MP at home to overcome obvious ethical issues) in
order to explore the pharmacokinetic properties of MP. First, we inves-
tigated MP samples for the presence of a compound with DDC-like
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MP has been postulated [7,16], but we did not ﬁnd it. In second instance,
we compared Levodopa AUC after intake of MP or standard Levodopa +
DDCI, ﬁnding a 3.5 fold lowermedian ratio. Taken as awhole, the present
ﬁndings do not support the presence of intrinsic DDCI-like activity. How-
ever, we cannot completely exclude a potential residual DDCI effect
played by the last Levodopa + DDCI intake 12-h before the challenge.
When Levodopawas administered at a 4-fold dose asMP powder in a pa-
tientwith advanced PD,we found a similar improvement inmotor symp-
toms along with longer ON duration and reduced dyskinesias (Table 2).
Although limited by the single-case description, these clinical data are
consistent with previous ﬁndings in human subjects [11,22]. Notably,
our patient used MP powder from roasted MP seeds without any addi-
tional compound or pharmaceutical process, while PD subjects in the pre-
vious clinical study were administered a pharmaceutical product
containing MP extract along with additives [11]. Using a 4-fold dose, the
AUC was slightly greater (1.7-fold) with MP than with Levodopa +
DDCI (Table 2, Fig. 2). Double-blind, randomized, controlled trials are re-
quired to assess the safety and efﬁcacy of MP powder obtained from raw
seeds in comparison to both Levodopa + DDCI and Levodopa without
DDCI.
5. Conclusion
MP contains a mean of 5.3% Levodopa, albeit with substantial vari-
ability according to ecotype and preparation method. The lack of alka-
loids indicates that MP is a safe source of Levodopa. If MP is safe and
effective in the long-term, it may become a sustainable therapeutic al-
ternative for patients with PD who live in tropical developing countries
and who cannot afford pharmacological Levodopa therapy.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jns.2016.04.001.
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